Legal Representation
Attorney
Victoria D Summerfield
USPTO Deadlines
Application History
13 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 20, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 20, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 20, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 7, 2025 | ATRV | O | ATTORNEY REVIEW COMPLETED | Loading... |
| Jul 21, 2025 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Jul 21, 2025 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jul 21, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 21, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 21, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 18, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 10, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 11, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Feb 11, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 040
Custom manufacturing services for others in the fields of viral-based and non-viral vectors, pharmaceuticals, biologics, vaccines, biotechnological medical products, and gene and cell therapy preparations
First Use Anywhere:
Oct 1, 2024
First Use in Commerce:
Oct 1, 2024
Class 042
Pharmaceutical research services; Pharmaceutical drug development and discovery services, namely, providing translational research tools and services, namely, providing scientific research in the field of screening, testing, sequencing, and analysis of DNA- and RNA-encoded genetic material for drug candidate development; cell and gene therapy product development services; Analytical services being scientific research services in the field of drug substance and drug product characterization which are for research use and in accordance with Good Manufacturing Practices (GMP); Preclinical services including pharmacology, pharmacokinetics, and toxicology in well established lab animal models; Scientific research and development and Good Laboratory Practices (GLP) services for bioanalytical testing including immunogenicity, biodistribution and shedding to support pre-clinical (animal) and clinical (human) studies; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing for quality control purposes and analytical scientific advisory services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Good Manufacturing Practices (GMP) laboratory and stability testing for quality control purposes and analytical scientific advisory services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Providing laboratory research services for others in accordance with the Clinical Laboratory Improvement Amendments (CLIA) program to support the development of gene and cell therapy, biologics, vaccines, pharmaceuticals, and related biotechnological products; Research and development relating to production and analysis of viral-based vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations for use in medical research for others
First Use Anywhere:
Oct 1, 2024
First Use in Commerce:
Oct 1, 2024
Additional Information
Pseudo Mark
FRANKLIN BIOLABS WORDMARK WITHOUT CLAIM TO FONT STYLE COLOR OR SIZE
Classification
International Classes
040
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
BIOLABS